Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Prostatic Neoplasms 1Non-small Cell Lung Cancer Adenocarcinoma 1Microsatellite Stable Colorectal Cancer 1Inflammatory Breast Neoplasms 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 1grapiprant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non-small Cell Lung Cancer Adenocarcinoma × grapiprant × Clear all
NCT03696212 2021-02-21

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Arrys Therapeutics

Phase 1/2 Terminated
18 enrolled
Thoracic

Non-small Cell Lung Cancer Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡